Company intelligence / Profile preview
Dauntless Pharmaceuticals
San Diego, California, United Statespharmaceutical.report ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Dauntless’s lead candidate DP1038, an intranasal octreotide formulation using Intravail® technology, has completed Phase I trials showing safety/tolerability comparable to subcutaneous injection. It has advanced to Phase II development targeting chemotherapy-induced diarrhea and endocrine disorders. The company leverages a one-company-per-drug model to accelerate development with lower costs.
No published pivotal efficacy results yet.
Pipeline breadth appears limited but focused; the business model allows rapid expansion if new assets are acquired/licensed.
Notable partnerships include Aegis Therapeutics for drug delivery tech.
- Therapeutic areas
- Oncology
- Modalities
- Peptides (notably octreotide acetate)Small molecules (potentially, based on pipeline focus)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Aegis Therapeutics – licensing agreement for Intravail® drug delivery technology.
Beyond the preview
Go deeper on Dauntless Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dauntless Pharmaceuticals.